ERNA.NASDAQEterna Therapeutics INC
10-K: Eterna Therapeutics Reports Annual Results, Cites Going Concern Uncertainty
Sentiment:
Annual Results
Eterna Therapeutics' 2024 10-K filing reveals significant losses, a going concern warning, and strategic shifts in their iMSC therapy development.
Capital raiseThe company will need to raise additional capital, which could be through the sales of shares of its common stock under the SEPA, public or private equity offerings, debt financings, out-licensing the Company's intellectual property, strategic partnerships or other means.
Worse than expectedThe company's net loss increased significantly from 2023 to 2024.The company expresses substantial doubt about its ability to continue as a going concern.The company's stockholders equity at December 31, 2024 was approximately $1.9 million.The company received notice from Nasdaq that it no longer met the Bid Price Rule and the MVLS Rule.
Summary
- Eterna Therapeutics' Form 10-K filing for the fiscal year ended December 31, 2024, highlights the company's financial status and strategic direction.
- The company is a preclinical-stage synthetic allogeneic iMSC therapy company focused on developing cellular therapies for solid tumors and autoimmune diseases.
- A significant net loss of $44.5 million was reported for 2024, contributing to an accumulated deficit of $231.5 million.
- Based on current financial conditions, the company expresses substantial doubt about its ability to continue as a going concern for the next 12 months.
- To address liquidity concerns, Eterna is considering various financing options, including equity offerings, debt financing, and strategic partnerships.
- The company is focusing on its lead product candidate, ERNA-101, for platinum-resistant ovarian cancer, with IND enabling studies and submission expected by 2026.
- A new Exclusive License and Collaboration Agreement with Factor Bioscience Limited was established, terminating previous agreements and securing exclusive licenses in key therapeutic areas.
- The company in-licensed 13 patent families, including 33 granted patents, to protect its iMSC technology platform.
- The company is actively seeking strategic partnerships to co-develop or out-license therapeutic assets.
- The company had six full-time employees as of March 10, 2025.
- The company is subject to extensive government regulation, including FDA approval processes for drugs and biologics.
- The company faces intense competition in the biotechnology and pharmaceutical industries.
- The company identified and remediated a prior material weakness in internal control over financial reporting as of December 31, 2024.
Sentiment
Score: 3
Explanation: The document presents a concerning financial situation with a going concern warning, significant losses, and Nasdaq listing compliance issues, overshadowing any positive developments.
Positives
- The company entered into an Exclusive License and Collaboration Agreement with Factor Bioscience Limited, securing exclusive licenses in key therapeutic areas.
- The company in-licensed 13 patent families, including 33 granted patents, to protect its iMSC technology platform.
- The company is actively seeking strategic partnerships to co-develop or out-license therapeutic assets.
- The company recognized a gain on lease termination of approximately $1.6 million for the year ended December 31, 2024, related to the Somerville sublease.
- The company identified and remediated a prior material weakness in internal control over financial reporting as of December 31, 2024.
Negatives
- The company reported a significant net loss of $44.5 million for the year ended December 31, 2024, and has an accumulated deficit of $231.5 million.
- The company expresses substantial doubt about its ability to continue as a going concern for the next 12 months.
- The company's stockholders equity at December 31, 2024 was approximately $1.9 million.
- The company received notice from Nasdaq that it no longer met the Bid Price Rule and the MVLS Rule.
Risks
- The company will require substantial additional capital to fund its operations, and if it fails to obtain the necessary financing, it may not be able to continue as a going concern.
- The company depends substantially on in-licensed intellectual property, and if it fails to comply with those obligations, it could lose license rights.
- The company's product development relies on novel, inherently risky technologies.
- The company is in an industry with intense competition and rapid technological change.
- Negative public opinion and increased regulatory scrutiny due to ethical and other concerns surrounding the use of stem cell therapy or human tissue may damage public perception of the company's product candidates.
- The company's failure to meet the continued listing requirements of Nasdaq could result in a delisting of its common stock.
Future Outlook
The company expects to complete IND enabling studies and submission for ERNA-101 by 2026 and is actively seeking strategic partnerships to co-develop or out-license therapeutic assets.
Industry Context
The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition, and a strong emphasis on proprietary products. Eterna Therapeutics competes with both existing MSC-based therapies and emerging technologies.
Comparison to Industry Standards
- Mesoblast, an Australia-based regenerative medicine company, was the first to launch an MSC-based therapy RYONCIL in the U.S. for the treatment of steroid-refractory acute graft-versus-host disease (GVHD).
- Other U.S. based companies like BrainStorm Cell Therapeutics, RESTEM, Celltex, Baylx, Calidi Bio, Akan Biosciences, among others, are developing MSC therapies in solid tumor and inflammatory diseases.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| President and Chief Executive Officer | Matthew Angel | Sanjeev Luther | January 1, 2024 | Not specified |
Legal Proceedings
- The company is involved in litigation and arbitrations from time to time in the ordinary course of business.
- Novellus, Inc. filed a complaint in the Superior Court of Massachusetts, Suffolk County, against former Novellus, Inc. employees Paul Sowyrda and John Westman and certain other former investors in Novellus LLC, alleging breach of fiduciary duty, breach of contract and civil conspiracy.
- eTheRNA Immunotherapies NV and eTheRNA Inc. filed a complaint against the Company alleging federal trademark infringement, federal unfair competition, Massachusetts state common law trademark infringement, and Massachusetts state unfair competition; the parties settled the claims and stipulated to dismiss the complaint with prejudice.
Related Party Transactions
- The company entered into agreements with Factor Bioscience Inc. and/or Dr. Matthew Angel, which have been deemed related party transactions because the company's former chief executive officer, Dr. Angel, is the chairman and chief executive officer of Factor Bioscience Inc. and a director of its subsidiary, Factor Bioscience Limited.
- The company closed the Exacis Acquisition, which was deemed a related party transaction because, at the time of the acquisition, (i) Dr. Gregory Fiore was both the chief executive officer of Exacis and a member of the company's board of directors, (ii) Dr. Angel was both the company's chief executive officer and chairman of Exacis scientific advisory board, and (iii) an affiliate of Factor Bioscience was the majority stockholder of Exacis.
- The company entered into a consulting agreement with Dr. Fiore, whereby Dr. Fiore agreed to provide business development consulting services to the company for a monthly retainer of $20,000.
- Investors in the July 2023 Convertible Note financing included Brant Binder, Richard Wagner, Charles Cherington and Nicholas Singer, and investors in the December 2023 Convertible Note financing and the September 2024 financing included Messrs. Cherington and Singer.
Stakeholder Impact
- Shareholders may experience dilution from potential future sales of common stock or securities convertible into common stock.
- Employees may be affected by potential cost-cutting measures or changes in operations due to the company's financial situation.
- The company's ability to develop and commercialize product candidates may be impacted by its financial situation and ability to secure funding.
- The company's relationships with suppliers and partners may be affected by its financial situation.
Next Steps
- The company expects to complete IND enabling studies and submission for ERNA-101 by 2026.
- The company is actively seeking strategic partnerships to co-develop or out-license therapeutic assets.
Key Dates
| Date | Description |
|---|---|
| 2011-12-05 | Earliest effective date of patent application for FAB-001: Methods and Products for Transfecting Cells |
| 2012-05-07 | Earliest effective date of patent application for FAB-003: Methods and Products for Transfection |
| 2012-11-01 | Earliest effective date of patent application for FAB-005: Methods and Products for Expressing Proteins in Cells |
| 2016-02-16 | Earliest effective date of patent application for FAB-009: Nucleic Acid Products and Methods of Administration Thereof |
| 2017-08-17 | Earliest effective date of patent application for FAB-010: Nucleic Acid Products and Methods of Administration Thereof |
| 2019-03-27 | Earliest effective date of patent application for FAB-011: Nucleic Acid-Based Therapeutics |
| 2019-04-18 | Date of PIPE Investor Common Warrants |
| 2021-05-12 | Earliest effective date of patent application for FAB-013: Engineered Gene-Editing Proteins |
| 2021-06-16 | Date of employment agreement with Sandra Gurrola |
| 2022-01-01 | Start of period for error correction in financial statements |
| 2022-03-31 | Date of PIPE Investor Common Warrants |
| 2022-04-27 | Earliest effective date of patent application for FAB-018: Circular RNA |
| 2022-05-03 | Date of ERSquibbSonsLLCMember |
| 2022-06-30 | Aggregate market value of common stock held by non-affiliates |
| 2022-09-02 | Date of FactorBioscienceIncMember |
| 2022-09-24 | Date of PurchaseAgreementMember BridgeDebtMember |
| 2022-10-31 | Date of ERSquibbSonsLLCMember |
| 2022-12-31 | Date of DecemberTwoThousandTwentyTwoWarrantsMember |
| 2023-01-01 | Start of period for RetirementPlan401KMember |
| 2023-04-05 | Date of LincolnParkCapitalFundLLCMember StandbyEquityPurchaseAgreementMember |
| 2023-04-26 | Date of ExacisAssetPurchaseAgreementMember ContingentConsiderationOneMember |
| 2023-04-30 | Date of LincolnParkCapitalFundLLCMember |
| 2023-05-02 | Date of FactorBioscienceIncMember |
| 2023-07-14 | Date of JulyTwoThousandTwentyThreeConvertibleNotesMember JulyTwoThousandTwentyThreeWarrantsMember |
| 2023-07-31 | Date of JulyTwoThousandTwentyThreeConvertibleNotesMember |
| 2023-08-05 | Date of SubleaseTerminationAgreementMember |
| 2023-08-31 | Date of LineageAssignmentAgreementMember |
| 2023-12-08 | Date of LineageAssignmentAgreementMember FactorBioscienceLimitedMember |
| 2023-12-14 | Date of JulyTwoThousandTwentyThreeConvertibleNotesMember DecemberTwoThousandTwentyThreeConvertibleNotesMember DecemberTwoThousandTwentyThreeWarrantsMember |
| 2023-12-15 | Date of DecemberTwoThousandTwentyThreeConvertibleNotesMember DecemberTwoThousandTwentyThreeWarrantsMember |
| 2023-12-31 | Date of DecemberTwoThousandTwentyTwoWarrantsMember |
| 2024-01-01 | Start of period for EquityIncentivePlanTwoThousandTwentyMember |
| 2024-01-11 | Date of DecemberTwoThousandTwentyThreeConvertibleNotesMember DecemberTwoThousandTwentyThreeWarrantsMember |
| 2024-04-26 | Date of PresidentChiefExecutiveOfficerAndDirectorMember NonQualifiedStockOptionMember |
| 2024-05-01 | Date of FactorBioscienceIncMember |
| 2024-05-03 | Date of ERSquibbSonsLLCMember |
| 2024-08-05 | Date of SubleaseTerminationAgreementMember |
| 2024-08-31 | Date of SubleaseTerminationAgreementMember |
| 2024-09-24 | Date of LineageAssignmentAgreementMember FactorBioscienceLimitedMember FactorLAndCAgreementMember FirstTwelveMonthsMember FirstNineMonthsMember PurchaseAgreementMember BridgeDebtMember ExchangeAgreementsMember SecuritiesPurchaseAgreementMember |
| 2024-10-01 | Date of BridgeDebtMember |
| 2024-10-29 | Date of ExchangeAgreementsMember PrefundedWarrantsMember BridgeDebtMember |
| 2024-11-01 | Date of BridgeDebtMember |
| 2024-12-24 | Date of PrefundedWarrantsMember |
| 2024-12-31 | End of fiscal year |
| 2025-03-10 | Date of report |
| 2025-03-11 | Date of MSALicenseFeesMember |
| 2025-04-01 | Date of FactorBioscienceIncMember |
| 2026 | Expected completion of IND enabling studies and submission for ERNA-101 |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.